3 Contract Formulations Company, Research Led Manufacturing Partner and Global Generics Leader Stocks With a Strong Future Roadmap: Innova Captab, Anthem Biosciences and Dr. Reddy's Laboratories

Contract pharma, biosciences and generics stocks let investors follow companies that serve a growing part of the Indian economy. Innova Captab, Anthem Biosciences and Dr. Reddy's Laboratories cover a contract formulations company, a research led manufacturing partner and a global generics leader.

This list covers three contract pharma, biosciences and generics stocks with complete current figures: Innova Captab, Anthem Biosciences and Dr. Reddy's Laboratories. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Contract Pharma, Biosciences and Generics Stocks?

Contract pharma, biosciences and generics stocks are listed pharmaceutical companies that manufacture formulations for other drug makers, develop and make drugs for global customers and sell generics, ingredients and branded products in many countries. Their earnings depend on contracts, approvals and export demand.

Contract Pharma, Biosciences and Generics Stocks at a Glance

On valuation, Dr. Reddy's Laboratories trades at a P/E below the industry P/E, while Innova Captab and Anthem Biosciences trade above it, which reflects the growth the market already expects. Readers comparing contract pharma, biosciences and generics stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Contract Pharma, Biosciences and Generics Stocks Have a Strong Roadmap in India?

Contract pharma, biosciences and generics stocks have a strong roadmap in India because outsourcing of drug development and manufacturing, new launches and global supply diversification keep widening the market for Indian pharmaceutical firms.

• Contract output. Drug makers outsource formulation work.
• Development partners. Global firms hand over complex programmes.
• Global generics. Launches broaden the revenue base.

Why Innova Captab Features Among These Contract Pharma, Biosciences and Generics Stocks

Among the contract pharma, biosciences and generics stocks on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.

The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0.

Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore.

Roadmap: The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

What to watch: Watch the growth in the branded business and the utilisation of expanded capacity.

Why Anthem Biosciences Features Among These Contract Pharma, Biosciences and Generics Stocks

Among the formulation outsourcing, CDMO and global generics shares on this list, Anthem Biosciences is a research-driven contract development and manufacturing organisation that serves global pharma and biotech customers with discovery, development and manufacturing services.

Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%.

The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0.

Roadmap: The company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.

What to watch: Monitor the order pipeline from global customers and the ramp-up of newer manufacturing capacity.

Why Dr. Reddy's Laboratories Features Among These Contract Pharma, Biosciences and Generics Stocks

Among the three companies on this list, Dr. Reddy's Laboratories is a Hyderabad-based pharmaceutical company that makes generics, active ingredients and branded products for India and global markets, with a large presence in North America and Europe.

Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%.

The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0.

Roadmap: The company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.

What to watch: Monitor launches of complex generics and the progress of biosimilar programmes.

Innova Captab vs Anthem Biosciences vs Dr. Reddy's Laboratories on Key Financials

The table below sets the three contract pharma, biosciences and generics stocks side by side on revenue, profit and margin, using reported figures.

Anthem Biosciences posts the highest return on equity in this group at 19.4%. Dr. Reddy's Laboratories has the largest FY26 revenue at Rs 35,059 crore, and Innova Captab shows the fastest revenue growth with a 19.5% compound annual rate. A useful habit with contract pharma, biosciences and generics stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Contract Pharma, Biosciences and Generics Stocks

Every theme carries risks that deserve a check before any decision. For these contract pharma, biosciences and generics stocks, the main points are:

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Currency moves. Export earnings move with the rupee.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter contract pharma, biosciences and generics stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Contract Pharma, Biosciences and Generics Stocks

Contract pharma, biosciences and generics stocks reward investors who follow demand trends, order books and margins together. Innova Captab, Anthem Biosciences and Dr. Reddy's Laboratories each have a clear plan to grow. Based on the 27 October 2026 close, Innova Captab trades at Rs 1,049.7, Anthem Biosciences at Rs 832.15 and Dr. Reddy's Laboratories at Rs 1,335.4.

Download the Univest iOS App or Univest Android App to track contract pharma, biosciences and generics stocks, set price alerts and get research-backed stock ideas.

What are contract pharma, biosciences and generics stocks?

Ans. Contract pharma, biosciences and generics stocks are listed pharmaceutical companies that manufacture formulations for other drug makers, develop and make drugs for global customers and sell generics, ingredients and branded products in many countries. Their earnings depend on contracts, approvals and export demand. This list looks at three of them, Innova Captab, Anthem Biosciences and Dr. Reddy's Laboratories, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.

Which contract pharma, biosciences and generics stocks are covered in this list?

Ans. This list covers Innova Captab, Anthem Biosciences and Dr. Reddy's Laboratories. Based on the 27 October 2026 close, Innova Captab traded at Rs 1,049.7, Anthem Biosciences at Rs 832.15 and Dr. Reddy's Laboratories at Rs 1,335.4. Their return on equity ranges from 11.1% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.3% to 19.5%.

Why do contract pharma, biosciences and generics stocks have a strong future roadmap in India?

Ans. Contract pharma, biosciences and generics stocks have a strong roadmap in India because outsourcing of drug development and manufacturing, new launches and global supply diversification keep widening the market for Indian pharmaceutical firms. The main drivers are as follows. Contract output. Drug makers outsource formulation work. Development partners. Global firms hand over complex programmes. Global generics. Launches broaden the revenue base. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Innova Captab performed financially?

Ans. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

How has Anthem Biosciences performed financially?

Ans. Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0. Looking ahead, the company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.

How has Dr. Reddy's Laboratories performed financially?

Ans. Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%. The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0. Looking ahead, the company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.

What risks should investors check before buying contract pharma, biosciences and generics stocks?

Ans. Investors should check a few risks before buying contract pharma, biosciences and generics stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of contract pharma, biosciences and generics stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.